Home » Stocks » TECH

Bio-Techne Corp (TECH)

Stock Price: $356.59 USD 0.91 (0.26%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 13.77B
Revenue (ttm) 759.65M
Net Income (ttm) 248.29M
Shares Out 38.54M
EPS (ttm) 6.26
PE Ratio 56.93
Forward PE 67.57
Dividend $1.28
Dividend Yield 0.36%
Trading Day January 22
Last Price $356.59
Previous Close $355.68
Change ($) 0.91
Change (%) 0.26%
Day's Open 356.13
Day's Range 353.28 - 358.26
Day's Volume 114,088
52-Week Range 160.61 - 358.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for...

Other stocks mentioned: RGLS
PRNewsWire - 2 months ago

MINNEAPOLIS, Nov. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stephens Annual ...

Seeking Alpha - 2 months ago

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q1 2021 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Techne (TECH) delivered earnings and revenue surprises of 25.44% and 9.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 2 months ago

MINNEAPOLIS, Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2020. First Quarter FY2021 Snapsho...

PRNewsWire - 2 months ago

MINNEAPOLIS, Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended Sep...

PRNewsWire - 2 months ago

MINNEAPOLIS, Nov. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stifel 2020 Virtu...

Zacks Investment Research - 2 months ago

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 months ago

NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and partner Bio-Tec...

PRNewsWire - 3 months ago

MINNEAPOLIS, Oct. 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module f...

PRNewsWire - 3 months ago

MINNEAPOLIS, Oct. 1, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace ...

PRNewsWire - 3 months ago

MINNEAPOLIS, Sept. 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufactu...

PRNewsWire - 4 months ago

MINNEAPOLIS, Sept. 22, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release ...

PRNewsWire - 4 months ago

MINNEAPOLIS, Sept. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic man...

PRNewsWire - 4 months ago

MINNEAPOLIS, Sept. 17, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V.

Investopedia - 4 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, INVA, MRSN, NVAX, REGN, VNDA, XBIT
PRNewsWire - 5 months ago

MINNEAPOLIS, Aug. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SAR...

Seeking Alpha - 5 months ago

Bio-Techne's (TECH) CEO Chuck Kummeth on Q4 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of Bio-Techne (NASDAQ:TECH) were unchanged after the company reported Q4 results.

PRNewsWire - 5 months ago

MINNEAPOLIS, Aug. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2020.

PRNewsWire - 5 months ago

MINNEAPOLIS, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Julie L.

PRNewsWire - 5 months ago

MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences ...

Zacks Investment Research - 5 months ago

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors Business Daily - 6 months ago

Bio-Techne (TECH) is expected to report earnings on Aug. 4. The stock is now trading 1% below the 282.62 buy point from a second-stage cup without handle that it cleared earlier.

PRNewsWire - 6 months ago

MINNEAPOLIS, July 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caus...

PRNewsWire - 6 months ago

MINNEAPOLIS, July 20, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the RNAscope™ platform with the release of the miRNAscope™ Assay. The RNAscope ...

Zacks Investment Research - 6 months ago

Techne (TECH) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research - 6 months ago

REGN vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: REGN
PRNewsWire - 7 months ago

MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The ...

PRNewsWire - 7 months ago

MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows. GM...

Zacks Investment Research - 7 months ago

LGND vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: LGND
PRNewsWire - 7 months ago

MINNEAPOLIS, May 27, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the virtual Jefferies ...

PRNewsWire - 8 months ago

MINNEAPOLIS and NEW YORK, May 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences ...

Zacks Investment Research - 8 months ago

LGND vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: LGND
Seeking Alpha - 8 months ago

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Techne (TECH) delivered earnings and revenue surprises of 23.01% and 5.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 9 months ago

Biotech and drug manufacturing companies with the strength to weather further coronavirus storms.

Other stocks mentioned: ALXN, BIIB, JNJ, NVO
Zacks Investment Research - 9 months ago

REGN vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: REGN
Seeking Alpha - 11 months ago

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Techne (TECH) delivered earnings and revenue surprises of -5.26% and -3.50%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

GILD vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: GILD
Zacks Investment Research - 1 year ago

CELG vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: CELG
Seeking Alpha - 1 year ago

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Techne (TECH) delivered earnings and revenue surprises of -0.93% and 1.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Techne (TECH) delivered earnings and revenue surprises of -4.58% and -3.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

CBM vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: CBM
GuruFocus - 1 year ago

CEO of Bio-techne Corp (NASDAQ:TECH) Charles R. Kummeth (insider trades) sold 16,969 shares of TECH on 07/10/2019 at an average price of $213.12 a share.

GuruFocus - 1 year ago

CEO of Bio-techne Corp (NASDAQ:TECH) Charles R. Kummeth sold 33,031 shares of TECH on 07/09/2019 at an average price of $212.6 a share.

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provid... [Read more...]

Industry
Biotechnology
IPO Date
Feb 9, 1989
CEO
Charles Kummeth
Employees
2,300
Stock Exchange
NASDAQ
Ticker Symbol
TECH
Full Company Profile

Financial Performance

In 2020, Bio-Techne's revenue was $738.69 million, an increase of 3.46% compared to the previous year's $714.01 million. Earnings were $229.30 million, an increase of 138.67%.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Bio-Techne stock is "Buy." The 12-month stock price forecast is 328.56, which is a decrease of -7.86% from the latest price.

Price Target
$328.56
(-7.86% downside)
Analyst Consensus: Buy